Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Systemic Inflammatory Response Syndrome | 27 | 2024 | 622 | 4.380 |
Why?
|
Influenza, Human | 26 | 2024 | 1539 | 3.210 |
Why?
|
Sepsis | 23 | 2024 | 2606 | 2.390 |
Why?
|
Respiratory Syncytial Virus Infections | 10 | 2024 | 365 | 1.940 |
Why?
|
Respiratory Tract Infections | 12 | 2024 | 1008 | 1.830 |
Why?
|
Critical Care | 24 | 2024 | 2712 | 1.760 |
Why?
|
Critical Illness | 23 | 2024 | 2744 | 1.650 |
Why?
|
Intensive Care Units, Pediatric | 25 | 2024 | 1019 | 1.620 |
Why?
|
Acute Lung Injury | 8 | 2023 | 377 | 1.550 |
Why?
|
Respiration, Artificial | 33 | 2023 | 2709 | 1.340 |
Why?
|
Child | 142 | 2024 | 80564 | 1.280 |
Why?
|
Intensive Care Units | 22 | 2024 | 3800 | 1.240 |
Why?
|
Multiple Organ Failure | 9 | 2024 | 390 | 1.190 |
Why?
|
Shock, Septic | 8 | 2024 | 774 | 1.180 |
Why?
|
Mannose-Binding Lectin | 2 | 2019 | 146 | 1.090 |
Why?
|
Respiratory Insufficiency | 7 | 2023 | 1240 | 1.090 |
Why?
|
Pediatrics | 15 | 2020 | 3606 | 1.020 |
Why?
|
Ribavirin | 5 | 2010 | 395 | 1.000 |
Why?
|
Infant | 60 | 2024 | 36386 | 0.920 |
Why?
|
Methicillin-Resistant Staphylococcus aureus | 3 | 2022 | 705 | 0.920 |
Why?
|
Haplotypes | 6 | 2017 | 2728 | 0.920 |
Why?
|
Influenza A Virus, H1N1 Subtype | 5 | 2022 | 452 | 0.890 |
Why?
|
Vitamin D-Binding Protein | 2 | 2015 | 129 | 0.880 |
Why?
|
Influenza A virus | 4 | 2020 | 453 | 0.860 |
Why?
|
Catheterization, Central Venous | 13 | 2011 | 539 | 0.860 |
Why?
|
Child, Preschool | 62 | 2024 | 42500 | 0.820 |
Why?
|
Pneumonia, Staphylococcal | 2 | 2022 | 38 | 0.820 |
Why?
|
Ventilator Weaning | 6 | 2010 | 170 | 0.790 |
Why?
|
Interferon Type I | 2 | 2023 | 567 | 0.780 |
Why?
|
Bacterial Infections | 4 | 2023 | 1387 | 0.780 |
Why?
|
Antiviral Agents | 8 | 2020 | 3050 | 0.720 |
Why?
|
Water-Electrolyte Balance | 3 | 2013 | 325 | 0.710 |
Why?
|
Randomized Controlled Trials as Topic | 18 | 2017 | 10383 | 0.710 |
Why?
|
Catheter-Related Infections | 5 | 2016 | 279 | 0.690 |
Why?
|
Respiratory Syncytial Viruses | 3 | 2023 | 168 | 0.680 |
Why?
|
Adolescent | 72 | 2024 | 88835 | 0.670 |
Why?
|
Connective Tissue Diseases | 4 | 2023 | 284 | 0.670 |
Why?
|
Immunity, Innate | 5 | 2022 | 3081 | 0.660 |
Why?
|
Humans | 218 | 2024 | 765968 | 0.630 |
Why?
|
Heart Arrest | 3 | 2016 | 1516 | 0.630 |
Why?
|
Ventilator-Induced Lung Injury | 3 | 2019 | 135 | 0.620 |
Why?
|
Acetaminophen | 2 | 2021 | 547 | 0.610 |
Why?
|
Bacteremia | 6 | 2016 | 989 | 0.600 |
Why?
|
Pulmonary Surfactants | 5 | 2023 | 169 | 0.600 |
Why?
|
Medical Staff, Hospital | 4 | 2020 | 601 | 0.580 |
Why?
|
Anti-Bacterial Agents | 6 | 2020 | 7478 | 0.550 |
Why?
|
Enterovirus D, Human | 1 | 2016 | 5 | 0.550 |
Why?
|
Bronchiolitis, Viral | 2 | 2015 | 82 | 0.540 |
Why?
|
Pandemics | 12 | 2024 | 8703 | 0.530 |
Why?
|
Erythrocyte Transfusion | 4 | 2016 | 568 | 0.520 |
Why?
|
Staphylococcal Infections | 3 | 2022 | 1393 | 0.520 |
Why?
|
Drug Utilization | 2 | 2019 | 1187 | 0.520 |
Why?
|
Hospitalization | 26 | 2024 | 10808 | 0.520 |
Why?
|
Research Personnel | 3 | 2022 | 590 | 0.520 |
Why?
|
Ethics Committees, Research | 3 | 2014 | 197 | 0.510 |
Why?
|
Enterovirus Infections | 1 | 2016 | 74 | 0.510 |
Why?
|
Multicenter Studies as Topic | 5 | 2014 | 1731 | 0.510 |
Why?
|
Immunoglobulins, Intravenous | 5 | 2023 | 669 | 0.510 |
Why?
|
Analgesics, Non-Narcotic | 1 | 2019 | 366 | 0.510 |
Why?
|
Orthomyxoviridae | 2 | 2016 | 147 | 0.500 |
Why?
|
Vancomycin | 1 | 2019 | 504 | 0.500 |
Why?
|
Candidemia | 1 | 2016 | 46 | 0.500 |
Why?
|
Journal Impact Factor | 1 | 2016 | 157 | 0.480 |
Why?
|
Personnel Staffing and Scheduling | 2 | 2017 | 499 | 0.470 |
Why?
|
Adrenergic alpha-Agonists | 1 | 2015 | 175 | 0.470 |
Why?
|
Vitamin D Deficiency | 2 | 2015 | 1348 | 0.460 |
Why?
|
Unconsciousness | 2 | 2015 | 250 | 0.460 |
Why?
|
Fluid Therapy | 4 | 2020 | 584 | 0.460 |
Why?
|
Evidence-Based Medicine | 13 | 2021 | 3685 | 0.450 |
Why?
|
Clinical Trials as Topic | 10 | 2020 | 8041 | 0.450 |
Why?
|
Adrenergic beta-Agonists | 1 | 2015 | 345 | 0.440 |
Why?
|
Infant, Newborn | 32 | 2024 | 26346 | 0.440 |
Why?
|
Pneumonia, Viral | 5 | 2022 | 3223 | 0.410 |
Why?
|
Influenza Vaccines | 4 | 2022 | 778 | 0.410 |
Why?
|
Ventilators, Mechanical | 4 | 2005 | 291 | 0.410 |
Why?
|
Catheters, Indwelling | 6 | 2005 | 438 | 0.400 |
Why?
|
Oseltamivir | 1 | 2012 | 75 | 0.400 |
Why?
|
Polymorphism, Genetic | 5 | 2005 | 4247 | 0.400 |
Why?
|
Cross Infection | 10 | 2011 | 1427 | 0.390 |
Why?
|
Epinephrine | 1 | 2015 | 783 | 0.390 |
Why?
|
RNA-Binding Proteins | 2 | 2017 | 1874 | 0.380 |
Why?
|
Polymorphism, Single Nucleotide | 8 | 2022 | 16047 | 0.370 |
Why?
|
Respiratory Syncytial Virus, Human | 1 | 2014 | 150 | 0.370 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2015 | 340 | 0.370 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2016 | 618 | 0.360 |
Why?
|
Hospital Bed Capacity | 2 | 2019 | 200 | 0.360 |
Why?
|
Drug Costs | 1 | 2019 | 1193 | 0.360 |
Why?
|
Coronavirus Infections | 4 | 2020 | 3100 | 0.360 |
Why?
|
Respiratory Distress Syndrome, Newborn | 2 | 2003 | 239 | 0.360 |
Why?
|
Hospital Information Systems | 2 | 2007 | 396 | 0.350 |
Why?
|
Hemoglobins | 2 | 2014 | 1530 | 0.350 |
Why?
|
Hypothermia, Induced | 1 | 2015 | 752 | 0.340 |
Why?
|
Genetic Predisposition to Disease | 9 | 2023 | 18071 | 0.340 |
Why?
|
Continuity of Patient Care | 1 | 2017 | 1078 | 0.340 |
Why?
|
Virus Diseases | 1 | 2016 | 718 | 0.340 |
Why?
|
Mutation, Missense | 1 | 2019 | 2589 | 0.330 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1946 | 0.330 |
Why?
|
Heparin | 5 | 2014 | 1630 | 0.320 |
Why?
|
Clinical Protocols | 3 | 2005 | 1441 | 0.320 |
Why?
|
Hospitals, Pediatric | 7 | 2022 | 1846 | 0.320 |
Why?
|
Female | 79 | 2024 | 396112 | 0.310 |
Why?
|
Male | 72 | 2024 | 363698 | 0.310 |
Why?
|
Burnout, Professional | 1 | 2017 | 711 | 0.300 |
Why?
|
Glucocorticoids | 6 | 2023 | 2132 | 0.300 |
Why?
|
Anticoagulants | 8 | 2021 | 4862 | 0.300 |
Why?
|
Respiratory Sounds | 4 | 2010 | 705 | 0.300 |
Why?
|
Euthanasia, Passive | 2 | 1999 | 64 | 0.290 |
Why?
|
Anesthesia | 2 | 2016 | 1590 | 0.290 |
Why?
|
Decision Support Techniques | 6 | 2009 | 2003 | 0.290 |
Why?
|
Nervous System Diseases | 3 | 2023 | 1660 | 0.280 |
Why?
|
Vaccines, Synthetic | 4 | 2022 | 621 | 0.280 |
Why?
|
United States | 40 | 2024 | 72903 | 0.280 |
Why?
|
Decision Support Systems, Clinical | 2 | 2022 | 1175 | 0.280 |
Why?
|
Vitamin D | 3 | 2015 | 3272 | 0.270 |
Why?
|
Prospective Studies | 19 | 2023 | 54802 | 0.270 |
Why?
|
Syndrome | 3 | 2024 | 3271 | 0.270 |
Why?
|
Biomedical Research | 3 | 2016 | 3458 | 0.270 |
Why?
|
Autoantibodies | 3 | 2024 | 2113 | 0.260 |
Why?
|
Respiration Disorders | 3 | 2009 | 362 | 0.260 |
Why?
|
Resuscitation | 3 | 2022 | 679 | 0.250 |
Why?
|
Catheterization, Peripheral | 5 | 2011 | 349 | 0.250 |
Why?
|
Venous Thrombosis | 2 | 2014 | 1327 | 0.250 |
Why?
|
Lymphotoxin-alpha | 1 | 2005 | 94 | 0.240 |
Why?
|
Personnel, Hospital | 1 | 2007 | 286 | 0.230 |
Why?
|
Superinfection | 1 | 2004 | 61 | 0.230 |
Why?
|
Asthma | 5 | 2022 | 6270 | 0.230 |
Why?
|
Lung Compliance | 1 | 2004 | 207 | 0.230 |
Why?
|
Equipment Contamination | 5 | 2002 | 183 | 0.230 |
Why?
|
Hospital Mortality | 6 | 2024 | 5343 | 0.220 |
Why?
|
Herpes Genitalis | 2 | 1996 | 148 | 0.220 |
Why?
|
Infection Control | 7 | 2011 | 983 | 0.220 |
Why?
|
Tidal Volume | 2 | 2013 | 519 | 0.220 |
Why?
|
Membrane Proteins | 2 | 2017 | 7851 | 0.220 |
Why?
|
Adrenal Cortex Hormones | 4 | 2010 | 1880 | 0.220 |
Why?
|
Haploinsufficiency | 2 | 2022 | 334 | 0.210 |
Why?
|
Molecular Mimicry | 1 | 2024 | 210 | 0.210 |
Why?
|
Guidelines as Topic | 2 | 2020 | 1394 | 0.210 |
Why?
|
Severity of Illness Index | 8 | 2022 | 15880 | 0.210 |
Why?
|
Pregnancy Complications, Infectious | 4 | 2022 | 2187 | 0.210 |
Why?
|
Drug Industry | 1 | 2009 | 791 | 0.210 |
Why?
|
Chromosomes, Human, Pair 5 | 1 | 2004 | 386 | 0.210 |
Why?
|
NF-kappa B p52 Subunit | 1 | 2022 | 35 | 0.210 |
Why?
|
Meningitis, Aseptic | 1 | 2023 | 59 | 0.210 |
Why?
|
Medical Records Systems, Computerized | 2 | 2007 | 1195 | 0.200 |
Why?
|
Macrophage Activation Syndrome | 1 | 2023 | 124 | 0.200 |
Why?
|
Withholding Treatment | 1 | 2007 | 621 | 0.200 |
Why?
|
Hospital Restructuring | 1 | 2002 | 11 | 0.200 |
Why?
|
Cross Reactions | 1 | 2024 | 824 | 0.200 |
Why?
|
Extracorporeal Membrane Oxygenation | 3 | 2023 | 1480 | 0.190 |
Why?
|
Vaccination | 9 | 2023 | 3426 | 0.190 |
Why?
|
Multigene Family | 1 | 2005 | 1080 | 0.190 |
Why?
|
Patient Selection | 5 | 2020 | 4255 | 0.190 |
Why?
|
Monitoring, Physiologic | 2 | 2007 | 1792 | 0.190 |
Why?
|
Interleukin-12 | 1 | 2004 | 579 | 0.190 |
Why?
|
Interleukin 1 Receptor Antagonist Protein | 1 | 2023 | 297 | 0.190 |
Why?
|
Data Interpretation, Statistical | 2 | 2009 | 2686 | 0.190 |
Why?
|
Immunity, Maternally-Acquired | 1 | 2022 | 112 | 0.190 |
Why?
|
Practice Guidelines as Topic | 5 | 2014 | 7425 | 0.190 |
Why?
|
Guillain-Barre Syndrome | 1 | 2023 | 128 | 0.180 |
Why?
|
Age Factors | 9 | 2022 | 18380 | 0.180 |
Why?
|
Immunoglobulins | 1 | 2004 | 852 | 0.180 |
Why?
|
Lymphopenia | 1 | 2023 | 297 | 0.180 |
Why?
|
Heparin, Low-Molecular-Weight | 2 | 2014 | 345 | 0.180 |
Why?
|
Models, Anatomic | 1 | 2004 | 677 | 0.180 |
Why?
|
Probability | 5 | 2009 | 2475 | 0.170 |
Why?
|
Antibodies, Viral | 4 | 2024 | 3211 | 0.170 |
Why?
|
Child, Hospitalized | 1 | 2022 | 181 | 0.170 |
Why?
|
Tachycardia, Supraventricular | 1 | 2022 | 270 | 0.170 |
Why?
|
Life Support Care | 2 | 2022 | 226 | 0.160 |
Why?
|
Young Adult | 14 | 2024 | 59889 | 0.160 |
Why?
|
Intubation, Intratracheal | 3 | 2010 | 1303 | 0.160 |
Why?
|
Steroids | 1 | 2004 | 933 | 0.160 |
Why?
|
Therapy, Computer-Assisted | 2 | 1998 | 265 | 0.160 |
Why?
|
Case-Control Studies | 12 | 2023 | 22223 | 0.160 |
Why?
|
Software Design | 2 | 1998 | 173 | 0.160 |
Why?
|
Immunocompromised Host | 1 | 2024 | 866 | 0.160 |
Why?
|
Anemia, Hemolytic, Autoimmune | 1 | 2020 | 147 | 0.160 |
Why?
|
Decision Making, Computer-Assisted | 1 | 1999 | 147 | 0.150 |
Why?
|
Retrospective Studies | 18 | 2024 | 81514 | 0.150 |
Why?
|
Asymptomatic Diseases | 1 | 2022 | 586 | 0.150 |
Why?
|
Adolescent Development | 1 | 2022 | 275 | 0.150 |
Why?
|
Tissue and Organ Procurement | 1 | 2007 | 989 | 0.150 |
Why?
|
Causality | 1 | 2024 | 1248 | 0.150 |
Why?
|
Venous Thromboembolism | 1 | 2011 | 1882 | 0.150 |
Why?
|
Bronchiolitis | 1 | 2004 | 493 | 0.150 |
Why?
|
Anti-Infective Agents | 2 | 2023 | 986 | 0.150 |
Why?
|
Informed Consent | 3 | 2014 | 1010 | 0.150 |
Why?
|
Epitopes | 1 | 2024 | 2523 | 0.150 |
Why?
|
Pulmonary Embolism | 1 | 2011 | 2598 | 0.140 |
Why?
|
Receptors, Immunologic | 2 | 2022 | 1415 | 0.140 |
Why?
|
Catheterization, Swan-Ganz | 1 | 1998 | 87 | 0.140 |
Why?
|
Thrombophlebitis | 1 | 1998 | 286 | 0.140 |
Why?
|
Health Services Research | 2 | 2010 | 1808 | 0.140 |
Why?
|
Lung Injury | 1 | 2021 | 430 | 0.140 |
Why?
|
Injections, Intravenous | 1 | 2019 | 1377 | 0.140 |
Why?
|
Aftercare | 4 | 2022 | 911 | 0.130 |
Why?
|
Hemolysin Proteins | 1 | 2016 | 112 | 0.130 |
Why?
|
Host-Pathogen Interactions | 2 | 2022 | 1461 | 0.130 |
Why?
|
Toll-Like Receptor 4 | 1 | 2020 | 586 | 0.130 |
Why?
|
Interferon Regulatory Factor-3 | 1 | 2017 | 145 | 0.130 |
Why?
|
Tumor Necrosis Factor-alpha | 2 | 2020 | 4348 | 0.130 |
Why?
|
Enterovirus | 1 | 2016 | 69 | 0.130 |
Why?
|
Acute Disease | 5 | 2016 | 7232 | 0.130 |
Why?
|
Lung | 3 | 2024 | 10033 | 0.130 |
Why?
|
Health Care Rationing | 1 | 2019 | 436 | 0.130 |
Why?
|
Length of Stay | 7 | 2020 | 6485 | 0.130 |
Why?
|
Cytokines | 4 | 2023 | 7421 | 0.130 |
Why?
|
Leukocytes, Mononuclear | 1 | 2022 | 1857 | 0.130 |
Why?
|
Risk Factors | 15 | 2023 | 74840 | 0.130 |
Why?
|
Acyclovir | 1 | 1996 | 267 | 0.130 |
Why?
|
History, 21st Century | 1 | 2022 | 1574 | 0.120 |
Why?
|
Consensus | 5 | 2024 | 3202 | 0.120 |
Why?
|
Persistent Vegetative State | 1 | 1998 | 274 | 0.120 |
Why?
|
Postoperative Nausea and Vomiting | 1 | 2016 | 128 | 0.120 |
Why?
|
Phenotype | 5 | 2024 | 16721 | 0.120 |
Why?
|
Myocarditis | 1 | 2023 | 802 | 0.120 |
Why?
|
Survival Analysis | 5 | 2019 | 10070 | 0.120 |
Why?
|
Biological Availability | 1 | 2015 | 385 | 0.120 |
Why?
|
Hematopoietic Stem Cell Transplantation | 3 | 2022 | 5753 | 0.120 |
Why?
|
Amino Acid Substitution | 1 | 2019 | 1740 | 0.120 |
Why?
|
Receptors, Adrenergic, beta-2 | 1 | 2015 | 216 | 0.120 |
Why?
|
Ultrasonography, Doppler | 1 | 1996 | 460 | 0.110 |
Why?
|
Disease Susceptibility | 1 | 2021 | 1789 | 0.110 |
Why?
|
Hepatic Veno-Occlusive Disease | 1 | 2016 | 221 | 0.110 |
Why?
|
Treatment Outcome | 14 | 2021 | 65188 | 0.110 |
Why?
|
Communicable Diseases | 1 | 2022 | 874 | 0.110 |
Why?
|
Interferons | 3 | 2023 | 714 | 0.110 |
Why?
|
Cohort Studies | 9 | 2023 | 41649 | 0.110 |
Why?
|
NF-kappa B | 1 | 2022 | 2485 | 0.110 |
Why?
|
Hyperglycemia | 1 | 2022 | 1393 | 0.110 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2022 | 1354 | 0.110 |
Why?
|
Prognosis | 7 | 2009 | 29922 | 0.110 |
Why?
|
Nursing Staff, Hospital | 1 | 1997 | 350 | 0.110 |
Why?
|
Immunomodulation | 3 | 2023 | 547 | 0.110 |
Why?
|
Adult | 28 | 2023 | 223044 | 0.110 |
Why?
|
Fatty Alcohols | 1 | 2012 | 22 | 0.100 |
Why?
|
Heart Septal Defects, Atrial | 1 | 2016 | 452 | 0.100 |
Why?
|
Thrombosis | 2 | 2021 | 2949 | 0.100 |
Why?
|
Phosphatidylglycerols | 1 | 2012 | 35 | 0.100 |
Why?
|
Nasopharynx | 1 | 2016 | 419 | 0.100 |
Why?
|
Random Allocation | 1 | 2017 | 2395 | 0.100 |
Why?
|
Cluster Analysis | 3 | 2022 | 2721 | 0.100 |
Why?
|
Thrombocytopenia | 1 | 2020 | 1171 | 0.100 |
Why?
|
Homozygote | 1 | 2017 | 1775 | 0.100 |
Why?
|
Protein Isoforms | 1 | 2017 | 1718 | 0.100 |
Why?
|
Patient Discharge | 5 | 2022 | 3461 | 0.100 |
Why?
|
Risk Adjustment | 1 | 2016 | 596 | 0.100 |
Why?
|
Seasons | 3 | 2023 | 1524 | 0.100 |
Why?
|
Kidney Transplantation | 1 | 2007 | 4270 | 0.090 |
Why?
|
Quality Assurance, Health Care | 1 | 2002 | 2172 | 0.090 |
Why?
|
Confidence Intervals | 2 | 2012 | 2910 | 0.090 |
Why?
|
Statistics, Nonparametric | 3 | 2012 | 2844 | 0.090 |
Why?
|
RNA, Viral | 2 | 2017 | 2864 | 0.090 |
Why?
|
Specimen Handling | 1 | 2016 | 704 | 0.090 |
Why?
|
Bacterial Toxins | 1 | 2016 | 924 | 0.090 |
Why?
|
Drug Administration Schedule | 1 | 2019 | 4850 | 0.090 |
Why?
|
Databases, Factual | 3 | 2023 | 8067 | 0.090 |
Why?
|
Comorbidity | 2 | 2023 | 10563 | 0.090 |
Why?
|
Genetic Markers | 1 | 2017 | 2601 | 0.090 |
Why?
|
Antibodies, Bacterial | 1 | 2016 | 1476 | 0.090 |
Why?
|
Cross-Sectional Studies | 8 | 2023 | 26318 | 0.090 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2021 | 2136 | 0.090 |
Why?
|
Vascular Surgical Procedures | 1 | 1999 | 1485 | 0.090 |
Why?
|
Croup | 1 | 2010 | 22 | 0.090 |
Why?
|
Child Development | 1 | 2022 | 2327 | 0.080 |
Why?
|
Fibroblasts | 1 | 2020 | 4159 | 0.080 |
Why?
|
Counseling | 1 | 1998 | 1551 | 0.080 |
Why?
|
Disease Notification | 1 | 2010 | 95 | 0.080 |
Why?
|
Computers | 2 | 2022 | 588 | 0.080 |
Why?
|
Logistic Models | 5 | 2021 | 13266 | 0.080 |
Why?
|
Genotype | 5 | 2023 | 13024 | 0.080 |
Why?
|
Point-of-Care Systems | 1 | 1998 | 1217 | 0.080 |
Why?
|
Catheterization | 3 | 2002 | 1425 | 0.080 |
Why?
|
Computer Simulation | 2 | 2017 | 6255 | 0.080 |
Why?
|
Adaptive Immunity | 1 | 2013 | 734 | 0.080 |
Why?
|
Chemoprevention | 1 | 2011 | 327 | 0.080 |
Why?
|
MEDLINE | 2 | 1999 | 120 | 0.080 |
Why?
|
Chemokines | 1 | 2013 | 956 | 0.080 |
Why?
|
Stroke Volume | 4 | 2023 | 5596 | 0.080 |
Why?
|
Disease Progression | 5 | 2023 | 13632 | 0.080 |
Why?
|
RNA, Messenger | 4 | 2024 | 12768 | 0.070 |
Why?
|
Cesarean Section | 2 | 1996 | 1431 | 0.070 |
Why?
|
Periodicals as Topic | 1 | 1999 | 1462 | 0.070 |
Why?
|
Incidence | 4 | 2021 | 21480 | 0.070 |
Why?
|
Neutralization Tests | 2 | 2022 | 735 | 0.070 |
Why?
|
Research Design | 5 | 2020 | 6209 | 0.070 |
Why?
|
Combined Modality Therapy | 3 | 2021 | 8529 | 0.070 |
Why?
|
Promoter Regions, Genetic | 2 | 2017 | 5786 | 0.070 |
Why?
|
Age Distribution | 2 | 2021 | 2858 | 0.070 |
Why?
|
Medical Oncology | 1 | 1999 | 2339 | 0.070 |
Why?
|
Disease Outbreaks | 1 | 2016 | 1759 | 0.070 |
Why?
|
Chlamydia Infections | 1 | 1990 | 364 | 0.070 |
Why?
|
Repressor Proteins | 1 | 2017 | 2968 | 0.070 |
Why?
|
Hemorrhage | 2 | 2016 | 3461 | 0.070 |
Why?
|
Genetic Association Studies | 1 | 2015 | 2741 | 0.070 |
Why?
|
Predictive Value of Tests | 4 | 2010 | 15398 | 0.060 |
Why?
|
Teaching | 1 | 1994 | 1169 | 0.060 |
Why?
|
Respiratory Function Tests | 2 | 2004 | 1693 | 0.060 |
Why?
|
Vasoconstrictor Agents | 2 | 2020 | 655 | 0.060 |
Why?
|
Algorithms | 1 | 2007 | 14071 | 0.060 |
Why?
|
Ventricular Function, Left | 3 | 2023 | 3928 | 0.060 |
Why?
|
Evaluation Studies as Topic | 2 | 1998 | 1600 | 0.060 |
Why?
|
Anesthesiology | 1 | 2016 | 1135 | 0.060 |
Why?
|
Internet | 1 | 1998 | 3106 | 0.060 |
Why?
|
Fellowships and Scholarships | 2 | 2008 | 1135 | 0.060 |
Why?
|
Budgets | 1 | 2007 | 232 | 0.060 |
Why?
|
Biometry | 1 | 2008 | 571 | 0.060 |
Why?
|
Sorting Nexins | 1 | 2024 | 25 | 0.060 |
Why?
|
Cost-Benefit Analysis | 3 | 1996 | 5526 | 0.060 |
Why?
|
Interleukin-12 Subunit p40 | 1 | 2004 | 58 | 0.060 |
Why?
|
Microbiological Techniques | 1 | 2005 | 96 | 0.060 |
Why?
|
Oleic Acid | 1 | 2024 | 88 | 0.060 |
Why?
|
Carboxylic Ester Hydrolases | 1 | 2024 | 100 | 0.060 |
Why?
|
Pregnancy | 6 | 2023 | 30260 | 0.060 |
Why?
|
RNA, Messenger, Stored | 1 | 2023 | 5 | 0.060 |
Why?
|
Quality of Life | 2 | 2023 | 13462 | 0.060 |
Why?
|
Regression Analysis | 3 | 2021 | 6322 | 0.060 |
Why?
|
National Institutes of Health (U.S.) | 2 | 2024 | 791 | 0.060 |
Why?
|
Prejudice | 1 | 2008 | 567 | 0.050 |
Why?
|
Wounds and Injuries | 1 | 2016 | 2511 | 0.050 |
Why?
|
Research Support as Topic | 1 | 2008 | 696 | 0.050 |
Why?
|
Boston | 2 | 2014 | 9338 | 0.050 |
Why?
|
Brain Death | 1 | 2007 | 360 | 0.050 |
Why?
|
Infusions, Intravenous | 2 | 1998 | 2229 | 0.050 |
Why?
|
Puerto Rico | 1 | 2004 | 381 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 1997 | 3925 | 0.050 |
Why?
|
Quality of Health Care | 1 | 1998 | 4300 | 0.050 |
Why?
|
Decision Trees | 2 | 1998 | 509 | 0.050 |
Why?
|
Interleukin-15 | 1 | 2023 | 186 | 0.050 |
Why?
|
Methicillin | 1 | 2022 | 61 | 0.050 |
Why?
|
Linkage Disequilibrium | 2 | 2004 | 1997 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2013 | 12056 | 0.050 |
Why?
|
Aspirin | 1 | 2014 | 3134 | 0.050 |
Why?
|
Influenza B virus | 1 | 2022 | 53 | 0.050 |
Why?
|
Quality Control | 1 | 2005 | 837 | 0.050 |
Why?
|
Mothers | 2 | 2023 | 2210 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2014 | 39193 | 0.050 |
Why?
|
Inheritance Patterns | 1 | 2004 | 345 | 0.050 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2022 | 85 | 0.050 |
Why?
|
Rehabilitation | 1 | 2003 | 125 | 0.050 |
Why?
|
Blood | 1 | 2004 | 597 | 0.050 |
Why?
|
Leukocytosis | 1 | 2023 | 248 | 0.050 |
Why?
|
Chemotactic Factors | 1 | 2022 | 195 | 0.050 |
Why?
|
Pulmonary Surfactant-Associated Protein D | 1 | 2021 | 49 | 0.050 |
Why?
|
HLA-DR Antigens | 1 | 2023 | 608 | 0.050 |
Why?
|
Orthomyxoviridae Infections | 1 | 2024 | 254 | 0.050 |
Why?
|
Crowding | 1 | 2023 | 142 | 0.050 |
Why?
|
Physicians, Women | 1 | 2008 | 512 | 0.050 |
Why?
|
Staphylococcus aureus | 2 | 2022 | 1424 | 0.050 |
Why?
|
Patients | 1 | 2008 | 910 | 0.050 |
Why?
|
Neoplasms | 2 | 2022 | 22340 | 0.050 |
Why?
|
Costs and Cost Analysis | 1 | 2007 | 1668 | 0.050 |
Why?
|
Lymphocyte Count | 1 | 2023 | 790 | 0.050 |
Why?
|
Risk Assessment | 5 | 2014 | 24282 | 0.050 |
Why?
|
Oxygen | 1 | 2012 | 4241 | 0.040 |
Why?
|
Gene Expression Profiling | 3 | 2023 | 9525 | 0.040 |
Why?
|
Erythrocytes | 1 | 2010 | 2395 | 0.040 |
Why?
|
Stroke | 1 | 2023 | 9747 | 0.040 |
Why?
|
Respiratory Mechanics | 1 | 2004 | 717 | 0.040 |
Why?
|
Odds Ratio | 1 | 2012 | 9649 | 0.040 |
Why?
|
Linear Models | 2 | 2023 | 5876 | 0.040 |
Why?
|
Influenza in Birds | 1 | 2020 | 76 | 0.040 |
Why?
|
North America | 2 | 2016 | 1285 | 0.040 |
Why?
|
Automation | 1 | 2002 | 585 | 0.040 |
Why?
|
Birds | 1 | 2020 | 165 | 0.040 |
Why?
|
Receptor, Notch1 | 1 | 2023 | 517 | 0.040 |
Why?
|
Hematologic Neoplasms | 1 | 2011 | 1927 | 0.040 |
Why?
|
Immunization, Passive | 1 | 2022 | 616 | 0.040 |
Why?
|
Sex Distribution | 1 | 2004 | 2263 | 0.040 |
Why?
|
Faculty, Medical | 1 | 2008 | 1219 | 0.040 |
Why?
|
Reproducibility of Results | 4 | 2005 | 20124 | 0.040 |
Why?
|
Hemodynamics | 2 | 2020 | 4184 | 0.040 |
Why?
|
Immunization, Secondary | 1 | 2022 | 373 | 0.040 |
Why?
|
Immunoassay | 1 | 2022 | 741 | 0.040 |
Why?
|
Coronary Care Units | 1 | 2020 | 235 | 0.040 |
Why?
|
Shock | 1 | 2021 | 316 | 0.040 |
Why?
|
Organizational Innovation | 1 | 2002 | 541 | 0.040 |
Why?
|
Subclavian Vein | 1 | 1998 | 58 | 0.040 |
Why?
|
High-Frequency Ventilation | 1 | 2019 | 90 | 0.040 |
Why?
|
Viral Envelope Proteins | 1 | 2022 | 640 | 0.040 |
Why?
|
Anemia | 1 | 2008 | 1511 | 0.040 |
Why?
|
Antigens, Viral | 1 | 2022 | 995 | 0.040 |
Why?
|
Interleukin-10 | 1 | 2004 | 1183 | 0.040 |
Why?
|
Human Experimentation | 1 | 1999 | 124 | 0.040 |
Why?
|
Hypermedia | 1 | 1998 | 21 | 0.040 |
Why?
|
Phlebitis | 1 | 1998 | 34 | 0.040 |
Why?
|
APACHE | 1 | 1998 | 268 | 0.040 |
Why?
|
Adenosine | 1 | 2023 | 806 | 0.040 |
Why?
|
Antisepsis | 2 | 2011 | 16 | 0.040 |
Why?
|
Diagnosis, Differential | 2 | 2021 | 12976 | 0.040 |
Why?
|
Family Characteristics | 1 | 2023 | 1001 | 0.040 |
Why?
|
Infusions, Intra-Arterial | 1 | 1998 | 218 | 0.040 |
Why?
|
Proteins | 1 | 2012 | 5995 | 0.040 |
Why?
|
Nasal Lavage Fluid | 1 | 2017 | 17 | 0.040 |
Why?
|
Angiopoietin-2 | 1 | 2019 | 187 | 0.040 |
Why?
|
Reference Standards | 1 | 2021 | 1013 | 0.040 |
Why?
|
Mice | 5 | 2024 | 81819 | 0.040 |
Why?
|
Intensive Care Units, Neonatal | 1 | 2004 | 855 | 0.030 |
Why?
|
Efficiency, Organizational | 1 | 2002 | 697 | 0.030 |
Why?
|
Jugular Veins | 1 | 1998 | 211 | 0.030 |
Why?
|
Brazil | 1 | 2021 | 1248 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2023 | 4642 | 0.030 |
Why?
|
Phagocytosis | 1 | 2023 | 1520 | 0.030 |
Why?
|
Information Services | 1 | 1998 | 240 | 0.030 |
Why?
|
Tissue Donors | 1 | 2007 | 2395 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2004 | 2424 | 0.030 |
Why?
|
Terminology as Topic | 1 | 2004 | 1534 | 0.030 |
Why?
|
Pedigree | 1 | 2004 | 4526 | 0.030 |
Why?
|
Animal Experimentation | 1 | 2016 | 46 | 0.030 |
Why?
|
Virus Replication | 1 | 2024 | 2447 | 0.030 |
Why?
|
Adenosine Triphosphate | 1 | 2023 | 1999 | 0.030 |
Why?
|
Early Diagnosis | 1 | 2021 | 1187 | 0.030 |
Why?
|
Paracentesis | 1 | 2016 | 99 | 0.030 |
Why?
|
Interleukin-8 | 1 | 2019 | 700 | 0.030 |
Why?
|
T-Lymphocytes | 2 | 2024 | 10261 | 0.030 |
Why?
|
Methicillin Resistance | 1 | 2016 | 198 | 0.030 |
Why?
|
Reference Values | 1 | 2003 | 4908 | 0.030 |
Why?
|
Interferon-alpha | 1 | 2020 | 910 | 0.030 |
Why?
|
Antibodies | 1 | 2023 | 2417 | 0.030 |
Why?
|
Equipment Failure | 1 | 1998 | 578 | 0.030 |
Why?
|
Phosphoproteins | 1 | 2024 | 2446 | 0.030 |
Why?
|
Mucocutaneous Lymph Node Syndrome | 1 | 2020 | 537 | 0.030 |
Why?
|
Polydeoxyribonucleotides | 1 | 2016 | 136 | 0.030 |
Why?
|
Chi-Square Distribution | 2 | 2012 | 3432 | 0.030 |
Why?
|
Minority Groups | 1 | 2022 | 1207 | 0.030 |
Why?
|
S100 Proteins | 1 | 2015 | 217 | 0.030 |
Why?
|
Viral Load | 1 | 2024 | 3386 | 0.030 |
Why?
|
von Willebrand Factor | 1 | 2019 | 676 | 0.030 |
Why?
|
Wound Infection | 1 | 1997 | 244 | 0.030 |
Why?
|
Stromal Cells | 1 | 2020 | 1329 | 0.030 |
Why?
|
Animals | 7 | 2024 | 168764 | 0.030 |
Why?
|
Pilot Projects | 2 | 2022 | 8733 | 0.030 |
Why?
|
Documentation | 1 | 2021 | 916 | 0.030 |
Why?
|
Body Fluids | 1 | 2016 | 321 | 0.030 |
Why?
|
Hypnotics and Sedatives | 1 | 2002 | 1191 | 0.030 |
Why?
|
Lactic Acid | 1 | 2020 | 1137 | 0.030 |
Why?
|
Carbon Dioxide | 1 | 2019 | 1137 | 0.030 |
Why?
|
Electronic Health Records | 2 | 2023 | 4873 | 0.030 |
Why?
|
Vasodilator Agents | 1 | 2019 | 988 | 0.030 |
Why?
|
Research | 1 | 2003 | 1975 | 0.030 |
Why?
|
Antiemetics | 1 | 2016 | 185 | 0.030 |
Why?
|
Positive-Pressure Respiration | 1 | 2019 | 711 | 0.030 |
Why?
|
Cadherins | 1 | 2019 | 900 | 0.030 |
Why?
|
Mass Screening | 1 | 1990 | 5446 | 0.030 |
Why?
|
Decision Making | 2 | 1999 | 3965 | 0.030 |
Why?
|
Interferon-gamma | 1 | 2022 | 3160 | 0.030 |
Why?
|
Nitric Oxide | 1 | 2023 | 2143 | 0.030 |
Why?
|
Registries | 1 | 2010 | 8297 | 0.030 |
Why?
|
Antibodies, Neutralizing | 1 | 2023 | 2010 | 0.030 |
Why?
|
Teaching Materials | 1 | 1994 | 85 | 0.030 |
Why?
|
Platelet Count | 1 | 2016 | 782 | 0.030 |
Why?
|
Phylogeny | 1 | 2021 | 2832 | 0.030 |
Why?
|
Canada | 2 | 2010 | 2119 | 0.030 |
Why?
|
Propensity Score | 1 | 2021 | 1968 | 0.030 |
Why?
|
Diuretics | 1 | 2016 | 613 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2012 | 6203 | 0.030 |
Why?
|
Oxygen Inhalation Therapy | 1 | 1996 | 418 | 0.030 |
Why?
|
Sex Factors | 2 | 2008 | 10603 | 0.030 |
Why?
|
Ethics, Research | 1 | 2014 | 178 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2020 | 1727 | 0.030 |
Why?
|
Risk | 3 | 2002 | 9591 | 0.030 |
Why?
|
Arrhythmias, Cardiac | 1 | 2022 | 2247 | 0.030 |
Why?
|
Partial Pressure | 1 | 2012 | 245 | 0.030 |
Why?
|
Selection Bias | 1 | 2014 | 361 | 0.020 |
Why?
|
Prone Position | 1 | 2013 | 201 | 0.020 |
Why?
|
Weight Gain | 1 | 2022 | 2355 | 0.020 |
Why?
|
Blood Gas Analysis | 1 | 2013 | 380 | 0.020 |
Why?
|
Hypercapnia | 1 | 2013 | 259 | 0.020 |
Why?
|
Delivery of Health Care | 2 | 2022 | 5370 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2003 | 5302 | 0.020 |
Why?
|
Inflammation | 2 | 2023 | 10850 | 0.020 |
Why?
|
Base Sequence | 1 | 2022 | 12403 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2022 | 3690 | 0.020 |
Why?
|
Chest Pain | 1 | 1998 | 1100 | 0.020 |
Why?
|
User-Computer Interface | 1 | 1998 | 1405 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2023 | 3850 | 0.020 |
Why?
|
Drug Therapy, Combination | 1 | 2021 | 6309 | 0.020 |
Why?
|
Inpatients | 1 | 2023 | 2564 | 0.020 |
Why?
|
Retreatment | 1 | 2012 | 598 | 0.020 |
Why?
|
Alcohols | 1 | 2011 | 94 | 0.020 |
Why?
|
Epidemiologic Research Design | 1 | 2014 | 368 | 0.020 |
Why?
|
Bradycardia | 1 | 2012 | 302 | 0.020 |
Why?
|
Materials Management, Hospital | 1 | 2010 | 8 | 0.020 |
Why?
|
Gene Expression | 1 | 2023 | 7584 | 0.020 |
Why?
|
Obesity | 2 | 2023 | 13076 | 0.020 |
Why?
|
Esterases | 1 | 1990 | 89 | 0.020 |
Why?
|
Neutrophils | 1 | 2023 | 3776 | 0.020 |
Why?
|
Aged | 5 | 2023 | 171117 | 0.020 |
Why?
|
Blotting, Western | 1 | 2017 | 5020 | 0.020 |
Why?
|
Chlorhexidine | 1 | 2011 | 159 | 0.020 |
Why?
|
Colony Count, Microbial | 1 | 1990 | 326 | 0.020 |
Why?
|
Macrophages | 1 | 2024 | 5772 | 0.020 |
Why?
|
T-Lymphocytes, Regulatory | 1 | 2023 | 3111 | 0.020 |
Why?
|
Single-Cell Analysis | 1 | 2020 | 2535 | 0.020 |
Why?
|
Quantitative Trait Loci | 1 | 2017 | 2140 | 0.020 |
Why?
|
Mice, Knockout | 1 | 2024 | 14448 | 0.020 |
Why?
|
ROC Curve | 1 | 1997 | 3620 | 0.020 |
Why?
|
Reagent Kits, Diagnostic | 1 | 1990 | 238 | 0.020 |
Why?
|
Administration, Oral | 1 | 1996 | 4015 | 0.020 |
Why?
|
Chlamydia trachomatis | 1 | 1990 | 240 | 0.020 |
Why?
|
Antigens, CD | 1 | 2019 | 4025 | 0.020 |
Why?
|
Infant Mortality | 1 | 1993 | 751 | 0.020 |
Why?
|
Radiography | 1 | 2019 | 6919 | 0.020 |
Why?
|
Morbidity | 1 | 1993 | 1749 | 0.020 |
Why?
|
Activities of Daily Living | 1 | 1997 | 2415 | 0.020 |
Why?
|
Health Personnel | 2 | 2011 | 3390 | 0.020 |
Why?
|
Terminal Care | 1 | 1999 | 1774 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4562 | 0.020 |
Why?
|
Blood Specimen Collection | 1 | 2008 | 238 | 0.020 |
Why?
|
Signal Transduction | 2 | 2020 | 23601 | 0.020 |
Why?
|
Drug Combinations | 1 | 2012 | 2077 | 0.020 |
Why?
|
Mutation | 2 | 2021 | 30198 | 0.020 |
Why?
|
Brain Injuries | 1 | 1998 | 2060 | 0.020 |
Why?
|
Alleles | 1 | 2017 | 6897 | 0.020 |
Why?
|
Immunotherapy | 1 | 2022 | 4752 | 0.020 |
Why?
|
Family | 1 | 1997 | 3209 | 0.020 |
Why?
|
Mice, Inbred C57BL | 1 | 2024 | 22332 | 0.020 |
Why?
|
Fluorescent Antibody Technique | 1 | 1990 | 2476 | 0.020 |
Why?
|
Disease Management | 1 | 2016 | 2535 | 0.020 |
Why?
|
Demography | 1 | 2010 | 1641 | 0.020 |
Why?
|
Thrombolytic Therapy | 1 | 2014 | 2059 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2012 | 2354 | 0.010 |
Why?
|
Recurrence | 1 | 1996 | 8501 | 0.010 |
Why?
|
Europe | 1 | 2010 | 3423 | 0.010 |
Why?
|
Awards and Prizes | 1 | 2008 | 364 | 0.010 |
Why?
|
Health Care Costs | 1 | 1996 | 3242 | 0.010 |
Why?
|
Blood Pressure Monitors | 1 | 2002 | 33 | 0.010 |
Why?
|
DNA Methylation | 1 | 2017 | 4424 | 0.010 |
Why?
|
Umbilical Arteries | 1 | 2002 | 78 | 0.010 |
Why?
|
Lymphoma | 1 | 2011 | 1897 | 0.010 |
Why?
|
Pregnancy Outcome | 1 | 1993 | 2966 | 0.010 |
Why?
|
Respiratory Hypersensitivity | 1 | 2004 | 271 | 0.010 |
Why?
|
Leukocytes | 1 | 1990 | 2027 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2021 | 12807 | 0.010 |
Why?
|
Dexamethasone | 1 | 2009 | 1963 | 0.010 |
Why?
|
3' Untranslated Regions | 1 | 2004 | 515 | 0.010 |
Why?
|
Chromosomes, Human, Pair 1 | 1 | 2004 | 640 | 0.010 |
Why?
|
Schools, Medical | 1 | 2008 | 876 | 0.010 |
Why?
|
Introns | 1 | 2004 | 966 | 0.010 |
Why?
|
Aged, 80 and over | 2 | 2019 | 59489 | 0.010 |
Why?
|
Forecasting | 1 | 2010 | 2936 | 0.010 |
Why?
|
Guideline Adherence | 1 | 2011 | 2243 | 0.010 |
Why?
|
Parents | 1 | 2014 | 3592 | 0.010 |
Why?
|
Curriculum | 1 | 1994 | 3782 | 0.010 |
Why?
|
Anti-Infective Agents, Local | 1 | 2002 | 245 | 0.010 |
Why?
|
Anti-Inflammatory Agents | 1 | 2009 | 1808 | 0.010 |
Why?
|
Time Factors | 2 | 2012 | 40065 | 0.010 |
Why?
|
Professional Staff Committees | 1 | 1999 | 37 | 0.010 |
Why?
|
Ethical Review | 1 | 1999 | 27 | 0.010 |
Why?
|
Therapeutic Human Experimentation | 1 | 1999 | 43 | 0.010 |
Why?
|
Control Groups | 1 | 1999 | 106 | 0.010 |
Why?
|
Forced Expiratory Volume | 1 | 2004 | 1828 | 0.010 |
Why?
|
Double-Blind Method | 1 | 2012 | 12437 | 0.010 |
Why?
|
Middle Aged | 3 | 2019 | 223009 | 0.010 |
Why?
|
International Cooperation | 1 | 2005 | 1432 | 0.010 |
Why?
|
Myocardial Infarction | 1 | 1998 | 11499 | 0.010 |
Why?
|
Skin | 1 | 2011 | 4489 | 0.010 |
Why?
|
Antibiotic Prophylaxis | 1 | 2002 | 644 | 0.010 |
Why?
|
Research Subjects | 1 | 1999 | 247 | 0.010 |
Why?
|
Patient Advocacy | 1 | 1999 | 361 | 0.010 |
Why?
|
Personal Autonomy | 1 | 1999 | 315 | 0.010 |
Why?
|
Home Care Services | 1 | 2002 | 660 | 0.010 |
Why?
|
Chromosome Mapping | 1 | 2004 | 4618 | 0.010 |
Why?
|
Uncertainty | 1 | 1999 | 761 | 0.010 |
Why?
|
Models, Genetic | 1 | 2004 | 3449 | 0.010 |
Why?
|
Internship and Residency | 1 | 1994 | 5946 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2002 | 2778 | 0.010 |
Why?
|
Genetic Testing | 1 | 2004 | 3595 | 0.010 |
Why?
|
Hospitals | 1 | 2002 | 3888 | 0.000 |
Why?
|
Artificial Intelligence | 1 | 1996 | 2659 | 0.000 |
Why?
|